Cantor Fitzgerald Reiterates Overweight Rating on Tenax Therapeutics (TENX)

September 10, 2026 9:24 AM

Cantor Fitzgerald analyst Olivia Brayer Saunders reiterated an Overweight rating and $35.00 price target on Tenax Therapeutics (NASDAQ: TENX).The analyst ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found